has already submitted its initial response to USFDA.
"The company is sending further updates on the committed corrective actions," it said, adding that it was confident that these OAI classifications will not have an impact on disruption of supplies or the revenue from operations of these facilities.
At 09:54 am, Aurobindo Pharma
was trading 5.4 per cent lower at Rs 686 on the BSE, as compared to a 0.41 per cent rise in the S&P BSE Sensex. The counter has seen huge trading volumes with a combined 1.86 million shares changing hands on the NSE and BSE in the first 40 minutes of trade.